Braun Stacey Associates Inc. Sells 2,992 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Braun Stacey Associates Inc. trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,964 shares of the medical research company’s stock after selling 2,992 shares during the period. Braun Stacey Associates Inc.’s holdings in IQVIA were worth $11,840,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Capital Performance Advisors LLP purchased a new position in IQVIA during the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the 3rd quarter worth about $28,000. Versant Capital Management Inc raised its holdings in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA during the 2nd quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the second quarter worth approximately $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Price Performance

IQV stock opened at $192.68 on Monday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market capitalization of $34.97 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.98 and a beta of 1.51. The company’s fifty day moving average price is $226.95 and its 200-day moving average price is $228.24. IQVIA Holdings Inc. has a one year low of $189.63 and a one year high of $261.73.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on IQV shares. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Truist Financial cut their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. UBS Group lifted their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $259.13.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.